Entera Bio (ENTX) Operating Expenses (2019 - 2026)

Entera Bio (ENTX) has reported Operating Expenses for 8 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.

• Quarterly Operating Expenses rose 38.08% year-over-year to $3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.5 million (up 23.87% YoY) and the FY2025 annual result came in at $11.5 million, up 20.17% from the prior year.
• Operating Expenses climbed to $3.5 million in Q1 2026 per ENTX's latest filing, from $3.0 million in the prior quarter.
• Over the last five years, Operating Expenses for ENTX reached as high as $3.8 million in Q1 2022 and fell as low as $2.0 million in Q4 2023.
• A 5-year average of $2.7 million and a median of $2.7 million in 2025 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 58.85% — and 2023, when it plunged 42.53%.
• Year by year, Operating Expenses stood at $3.1 million in 2022, then slumped by 36.14% to $2.0 million in 2023, then gained by 19.05% to $2.3 million in 2024, then soared by 30.17% to $3.0 million in 2025, then grew by 16.34% to $3.5 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $3.5 million, $3.0 million, and $3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.